Dr. Jones reports GLP-1 agonists may outperform aspirin in colorectal cancer prevention and tolerability
Dr. Colton Jones presented findings from a retrospective analysis that compared GLP-1 receptor agonists with aspirin for primary prevention of colorectal cancer.
The analysis indicated that patients on GLP-1 agonists had a lower incidence of colorectal cancer than those taking aspirin, and they reported better tolerability.
Jones noted that these results could expand the therapeutic role of GLP-1 drugs, but emphasized that prospective studies are required to confirm the protective benefit.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention”
read at onclive ↗
comments(0)
5-min edit window · permanent after that